CA3139060A1 - Compositions and methods for treatment of ocular diseases - Google Patents

Compositions and methods for treatment of ocular diseases Download PDF

Info

Publication number
CA3139060A1
CA3139060A1 CA3139060A CA3139060A CA3139060A1 CA 3139060 A1 CA3139060 A1 CA 3139060A1 CA 3139060 A CA3139060 A CA 3139060A CA 3139060 A CA3139060 A CA 3139060A CA 3139060 A1 CA3139060 A1 CA 3139060A1
Authority
CA
Canada
Prior art keywords
antibiotic
hydrogel
hyaluronic acid
composition
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139060A
Other languages
English (en)
French (fr)
Inventor
Brenda K. Mann
Hee-Kyoung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiora Pharmaceuticals Inc
Original Assignee
EyeGate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EyeGate Pharmaceuticals Inc filed Critical EyeGate Pharmaceuticals Inc
Publication of CA3139060A1 publication Critical patent/CA3139060A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3139060A 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases Pending CA3139060A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842995P 2019-05-03 2019-05-03
US62/842,995 2019-05-03
PCT/US2020/030691 WO2020227002A1 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
CA3139060A1 true CA3139060A1 (en) 2020-11-12

Family

ID=70861542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139060A Pending CA3139060A1 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Country Status (9)

Country Link
US (2) US11376214B2 (https=)
EP (1) EP3962452A1 (https=)
JP (1) JP7334266B2 (https=)
KR (2) KR102649858B1 (https=)
CN (1) CN114025742A (https=)
CA (1) CA3139060A1 (https=)
IL (1) IL287802B2 (https=)
MX (1) MX2021013447A (https=)
WO (1) WO2020227002A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945858B2 (en) * 2010-09-03 2021-03-16 Globus Medical, Inc. Expandable interspinous process fixation device
GB202008857D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
GB202008853D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
CN112587475B (zh) * 2020-12-18 2022-09-13 华熙生物科技股份有限公司 一种载药凝胶及其制备方法
DE102023116924A1 (de) * 2023-06-27 2025-01-02 Carl Zeiss Meditec Ag Kit zur Verwendung in einer Augenoperation und ophthalmische viskoelastische Vorrichtung
WO2025155730A1 (en) * 2024-01-16 2025-07-24 Regents Of The University Of Minnesota Injectable hydrogel for embolization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312076T1 (de) * 2001-02-22 2005-12-15 Anika Therapeutics Inc Thiol-modifizierte hyaluronan-derivate
CA2703807C (en) * 2010-05-12 2017-10-24 Molly S. Shoichet Enhanced stability of inverse thermal gelling composite hydrogels
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US9782345B2 (en) * 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
EP3675873A4 (en) * 2017-09-01 2021-06-16 Pmidg, Llc Functionalized and crosslinked polymers
US12029753B2 (en) * 2017-09-19 2024-07-09 The Hong Kong University Of Science And Technology Biocompatible material and methods for making and using thereof

Also Published As

Publication number Publication date
IL287802B1 (en) 2024-05-01
MX2021013447A (es) 2022-02-11
KR20220004753A (ko) 2022-01-11
WO2020227002A1 (en) 2020-11-12
JP7334266B2 (ja) 2023-08-28
IL287802A (en) 2022-01-01
CN114025742A (zh) 2022-02-08
US20200345634A1 (en) 2020-11-05
US11376214B2 (en) 2022-07-05
KR20240038152A (ko) 2024-03-22
JP2022530837A (ja) 2022-07-01
EP3962452A1 (en) 2022-03-09
IL287802B2 (en) 2024-09-01
US20220287961A1 (en) 2022-09-15
KR102649858B1 (ko) 2024-03-20

Similar Documents

Publication Publication Date Title
US20220287961A1 (en) Compositions and methods for treatment of ocular diseases
CN107847604B (zh) 眼用原位凝胶处方
EP2785328B1 (en) Novel slow-releasing ophthalmic compositions comprising povidone iodine
Alase Sustained ophthalmic delivery of gatifloxacin from in situ gelling system
AU2014293665A1 (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
US20210290527A1 (en) Compositions and Methods for Treatment of Ocular Conditions
EP4260844B1 (en) Ophthalmological compositions comprising poloxamer
US20120101056A1 (en) Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
Taghi et al. Formulation, In-vitro Evaluation, and Animal Study of Levofloxacin/Tinidazole loaded pH-dependent In-Situ Gel for Ophthalmic Drug Delivery
CA3119363A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
CN119326771A (zh) 包含泊洛沙姆的眼科组合物
HK40105104A (en) Ophthalmological compositions comprising poloxamer
CN118121709A (zh) 一种眼用药物组合物及其制备方法、应用
Tan Prophylaxis against endopthalmitis in cataract surgery
CA3184336A1 (en) Composition comprising pepstatin and alginic acid or a salt thereof, and use thereof
HK1248100B (zh) 眼用原位凝胶处方

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240424

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250522

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251015

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251215